Benjamin F. Edwards & Company’s NovoCure NVCR Stock Holding History

Benjamin F. Edwards & Company’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-125	Closed	-$8K	–	1819
2023 Q1	$8K	Hold	125	–	–	﹤0.01%	1451
2022 Q4	$9K	Hold	125	–	–	﹤0.01%	1454
2022 Q3	$9K	Hold	125	–	–	﹤0.01%	1412
2022 Q2	$9K	Sell	125 -277	-69%	-$20.9K	﹤0.01%	1407
2022 Q1	$33K	Sell	402 -600	-60%	-$44.2K	﹤0.01%	1131
2021 Q4	$75K	Buy	1,002 +885	+756%	+$88.8K	﹤0.01%	948
2021 Q3	$14K	Hold	117	–	–	﹤0.01%	1313
2021 Q2	$26K	Hold	117	–	–	﹤0.01%	1170
2021 Q1	$15K	Hold	117	–	–	﹤0.01%	1270
2020 Q4	$20K	Hold	117	–	–	﹤0.01%	1148
2020 Q3	$13K	Hold	117	–	–	﹤0.01%	1208
2020 Q2	$7K	Hold	117	–	–	﹤0.01%	1355
2020 Q1	$8K	Buy	117 +17	+17%	+$1.34K	﹤0.01%	1329
2019 Q4	$8K	Buy	+100	New	+$8.07K	﹤0.01%	1485

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Benjamin F. Edwards & Company's NVCR Position: Q2 2023 in Review

Benjamin F. Edwards & Company sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 125 shares — an estimated $8K sold.

Benjamin F. Edwards & Company first reported a position in NVCR in Q4 2019 and held it in 14 quarters. The position peaked at $75K in Q4 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Benjamin F. Edwards & Company reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Benjamin F. Edwards & Company sold 125 NovoCure shares in Q2 2023, an estimated $8K.
Benjamin F. Edwards & Company first reported a position in NovoCure in Q4 2019 and held it in 14 quarters.
Benjamin F. Edwards & Company's NovoCure position peaked at $75K in Q4 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2023, filed 15 Aug 2023.